210 related articles for article (PubMed ID: 33740205)
1. A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
Gharzai LA; Szczygiel LA; Shumway DA; Bandos H; Julian TB; Mamounas EP; White J; De Los Santos JF; Basik M; Ganz PA; Jagsi R
Breast Cancer Res Treat; 2021 Jun; 187(3):777-784. PubMed ID: 33740205
[TBL] [Abstract][Full Text] [Related]
2. Omission of Breast Surgery in Exceptional Responders.
Tasoulis MK; Lee HB; Kuerer HM
Clin Breast Cancer; 2024 Jun; 24(4):310-318. PubMed ID: 38365541
[TBL] [Abstract][Full Text] [Related]
3. Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.
Nakamura K; Ishitobi M; Oshiro C; Shima H; Takahashi E; Nakayama T; Shien T; Saito K; Iwatani T; Seto Y; Terata K; Kutomi G; Ogawa T; Inaji H
In Vivo; 2023; 37(2):794-800. PubMed ID: 36881070
[TBL] [Abstract][Full Text] [Related]
4. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
Criscitiello C; Curigliano G; Burstein HJ; Wong S; Esposito A; Viale G; Giuliano M; Veronesi U; Santangelo M; Golshan M
Eur J Surg Oncol; 2016 Dec; 42(12):1780-1786. PubMed ID: 27825710
[TBL] [Abstract][Full Text] [Related]
5. Current and future role of neoadjuvant therapy for breast cancer.
Untch M; Konecny GE; Paepke S; von Minckwitz G
Breast; 2014 Oct; 23(5):526-37. PubMed ID: 25034931
[TBL] [Abstract][Full Text] [Related]
6. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
7. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
8. De-escalation towards omission is the tipping point of individualizing breast cancer surgery.
Heil J; Pfob A; Kuerer HM
Eur J Surg Oncol; 2020 Aug; 46(8):1543-1545. PubMed ID: 32241595
[TBL] [Abstract][Full Text] [Related]
9. How Can We Improve Education of Breast Surgeons Across Europe?
Kolacinska A
Chirurgia (Bucur); 2017; 112(4):365-366. PubMed ID: 28862111
[TBL] [Abstract][Full Text] [Related]
10. Surgeon and Radiation Oncologist Views on Omission of Adjuvant Radiotherapy for Older Women with Early-Stage Breast Cancer.
Shumway DA; Griffith KA; Sabel MS; Jones RD; Forstner JM; Bott-Kothari TL; Hawley ST; Jeruss J; Jagsi R
Ann Surg Oncol; 2017 Nov; 24(12):3518-3526. PubMed ID: 28748445
[TBL] [Abstract][Full Text] [Related]
11. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.
van la Parra RF; Kuerer HM
Breast Cancer Res; 2016 Mar; 18(1):28. PubMed ID: 26951131
[TBL] [Abstract][Full Text] [Related]
12. Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting.
Esposito AC; Crawford J; Sigurdson ER; Handorf EA; Hayes SB; Boraas M; Bleicher RJ
J Surg Res; 2018 Jan; 221():49-57. PubMed ID: 29229152
[TBL] [Abstract][Full Text] [Related]
13. De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer.
Tasoulis MK; Heil J; Kuerer HM
Curr Breast Cancer Rep; 2022; 14(4):135-141. PubMed ID: 35915668
[TBL] [Abstract][Full Text] [Related]
14. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
[TBL] [Abstract][Full Text] [Related]
15. Surgeons' knowledge and practices regarding the role of radiation therapy in breast cancer management.
Zhou J; Griffith KA; Hawley ST; Zikmund-Fisher BJ; Janz NK; Sabel MS; Katz SJ; Jagsi R
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1022-9. PubMed ID: 24161426
[TBL] [Abstract][Full Text] [Related]
16. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
Heil J; Kuerer HM; Pfob A; Rauch G; Sinn HP; Golatta M; Liefers GJ; Vrancken Peeters MJ
Ann Oncol; 2020 Jan; 31(1):61-71. PubMed ID: 31912797
[TBL] [Abstract][Full Text] [Related]
17. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy.
Teshome M; Kuerer HM
Eur J Surg Oncol; 2017 May; 43(5):865-874. PubMed ID: 28284519
[TBL] [Abstract][Full Text] [Related]
18. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
[TBL] [Abstract][Full Text] [Related]
19. Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.
Buchholz TA; Mittendorf EA; Hunt KK
J Natl Cancer Inst Monogr; 2015 May; 2015(51):11-4. PubMed ID: 26063878
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy in the treatment of breast cancer.
Teshome M; Hunt KK
Surg Oncol Clin N Am; 2014 Jul; 23(3):505-23. PubMed ID: 24882348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
